Summary Multidrug resistance (MDR) to anti-cancer agents is frequently associated with overexpression of the drug efflux transporter Pglycoprotein (Pgp) in cancer cells, ensuing drug expulsion and maintenance of tolerable intracellular levels of certain cytotoxic drugs. Pgp may also be present in normal tissue, providing protection against toxic substances, but the physiological role of Pgp is not fully understood. Recently, it was shown that Pgp also takes part in the transport of certain growth-regulating cytokines (Drach et al, 1996; Raghu et al, 1996) . Therefore, we studied the effect of the highly potent Pgp inhibitor PSC 833 (Glj) were 0.2 gIM and 0.7 gM respectively. Exposure to PSC 833 induced cell death by apoptosis in both cell types, as revealed by flow cytometry and detection of 3'-hydroxy ends of DNA (the result of DNA fragmentation associated with apoptosis), by terminal transferase-mediated dUTP-biotin nick end-labelling (TUNEL). Similar effects were not found in the hepatoma cell lines or the parental leukaemia lines. These results demonstrated a discriminating cytotoxicity of PSC 833 in two human leukaemia MDR variants, representing a possible therapeutic indication which warrants consideration during the ongoing clinical evaluation of this drug.
tive potential of antineoplastic agents in cancer treatment. Multidrug resistance (MDR) is believed to be a major cause of treatment failure and is frequently associated with os erexpression of the multidrug transporter P-glycoprotein (Pgp). which is an integral plasma membrane protein capable of drug expulsion and maintenance of tolerable intracellular levels of certain cvtotoxic drums (Juliano and Ling. 1976: Endicott and ). Pgp has a broad specificity for multiple xenobiotics (Pastan and Gottesman. 1987) . many of which are clinically important anti-cancer druas with diverse structures and mechanisms of action (Mulder et al. 1995) . Thus. Pgp expression has been shown to correlate negatiselv with chemosensitivitv and survival in some solid tumours and various haematological malignancies (Yuen and Sikic. 1994: concentrations that are associated with severe cardiac toxicits in patients (de Faire and Lundman. 1977: Candell et al. 1979 ). The immunosuppressive agent cyclosporin A (CsA) has been shown to be a highly potent inhibitor of Pgp both in cell lines (Slater et al. 1986a : Twentvman. 1988 ) and in animal models (Slater et al. 1986b : Meador et al. 1987 . Althouah CsA inhibits Pgp at clinically relevant concentrations. the immunosuppression induced by this agent may be detrimental to cancer patients. Combined regimens of CsA and chemotherapeutic agents are associated with substantial toxicity and increased hospital admissions for treatment of septicaemia in particular (Theis et al. 1997) .
Therefore. the introduction of a novel non-immunosuppressant and highly effective MDR modifying cyclosporin. PSC 833. has provided new perspectives for therapeutic MDR reversal. and the drug is currently undergoing extensive clinical esaluation.
PSC 833 is a cyclosporin D analogtue which is tenfold more potent than CsA with respect to MDR reversal (Boesch et al. 1991a (Boesch et al. . 1991b . Photolabelling experiments using Pgap-rich membrane fragments have demonstrated that CsA binds to Pgp in vitro (Akisama et al. 1988; Foxwell et al. 1989) . Similarly. PSC 833 has been shown to displace H-photoaffinity-labelled CsA from P.gp (Archinal-Mattheis et al. 1995 ) and compete with ['H]vsinblastine binding to Pgap at a low molar level. the equilibrium constant. K. being 35 nrt (Ferry et al. 1996) . Thus. PSC 833 appears to be suitable for arresting Pgp function in studies of the physiological role of Pgp.
Recently. it was shown that Pgp participates in the transport of interleukins. which are important for proliferation and differentiation of certain cell types (Drach et al. 1996 : Raghu et al. 1996 . In the present study. we investigated the effect of Pgp inhibition by PSC 833 on the proliferation of the MDR phenotype and the wild type of two pairs of human KGla and K562 leukaemia cells and a pair of human HB8065 hepatoma cells. The results demonstrate differential effects of PSC 833 on the viability and growth of these separate cell tvpes.
MATERIALS AND METHODS Chemicals
The leukaemia cell lines were propagated in RPMI-1640 medium (Bio Whittaker. Walkersville. MA. USA) and the hepatoma cell lines in Eagle s modified minimum essential medium (EMEM. Bio Whittaker). Both growth media were supplemented with 10% fetal calf serum. L-glutamine (0.05 inm ml-'). streptomycin (100 go ml-). penicillin (100 U ml-'). nystatin (40 U ml-') and Hepes (only K562 cell lines). The pnmary antibody MRK16 (Hamada and Tsuruo. 1986 (ATCC) . and human hepatoma cells. HB8065 (ATCC). were selected for our studies. These cell lines were exposed to stepwise increased drug concentrations in the culture medium and. finally. KGla/200 cells were maintained in medium containing 100 ng ml-' daunorubicin and vincristine (Lehne et al. 1995) . K5621150 in medium containing 150 nrm vincristine (Gruber et al. 1994 ) and HB8065/R in medium containing 125 ng ml epirubicin (Hall et al. 1991) . The parental cell lines (KG la/0. K562/0 and HB8065/S) and the corresponding resistant sublines were propagated as previously described (Gruber et al. 1994 : Lehne et al. 1995 Flow cytometry: immunofluorescence assay of Pgp expression Specific immunoflourescence was obtained by a three-layer staining technique. Cell suspensions were washed with phosphate-buffered saline/bovine serum albumin (PBS/BSA) and incubated on ice for 60 min with MRK16 (25 jig ml-') or Mouse IgG2a (25 jg ml-') in PBS/BSA. The second-and third-layer staining protocols were carried out with 100 g1 of biotinylated horse anti-mouse IgG (1:35 dilution in PBS/BSA) and 100 g1 of fluorescein isothiocyanate (FITC)-conjugated streptavidin (1:35 dilution in PBS/BSA) for 20-30 min each. respectively. with one PBS/BSA wash between them. Immunofluorescence distributions were generated using a FACScan flow cytometer (Becton Dickinson. San Jose. CA. USA) with a 15-mW argon ion laser tuned to 488 nm. FITC fluorescence of gated populations was collected through a bandpass filter (FL1. bandwidth 515-545 nm). Data from 10 000 events were collected and calculations of logarithmically amplified fluorescence values were performed in arithmetic mode using the LYSIS (Becton Dickinson) computer program. Each experiment was repeated at least three times.
Flow cytometry: intracellular accumulation of anthracyclines
The cells were grown in drug-free medium for 24 h prior to flow cytometric analysis. Then the cells were incubated for 120 min at 37CC with daunorubicin (4.4 jiN) alone or in combination with PSC 833 (0.04-4.1 jm). Immediately after. the cell samples were placed on ice and daunorubicin fluorescence was acquired by the FACScan flow cytometer using a bandpass filter of 564-606 nm (FL2). Correlated forward anale (a relative measure of cell size) and right angle (a measure of cell granularity) light scatter measurements were generated to exclude dead cells and debris. Analyses were performed as described above. Each experiment was repeated at least three times. 
Assessments of apoptosis
Flow cytometric assessment of apoptosis utilizes a combination of the terminal transferase-mediated dUTP-biotin nick end-labelling (TUNEL) technique and the hypodiploidy assay. The method is based on template-independent addition of deoxynucleoside triphosphates to 3'-hydroxy ends of DNA (sites of DNA break) catalysed by the enzyme terminal deoxynucleotidyl transferase 
Pgp function
The cvtotoxic daunorubicin is a known substrate of Pgp (Scambia et al. 1994) and. thus. PSC 833 interferes with the transmembrane transport of this anti-cancer agent. Therefore. we assessed Pgp function by flow cytometric determination of daunorubicin accumulation in both the parental and the resistant subline of KGla cells in terms of drug fluorescence after 120 min incubation with 4.4 Am of the anti-cancer agent alone or in combination with PSC 833 at different concentrations. The accumulation of daunorubicin was dependent on cell type and the concentration of PSC 833. In the absence of PSC 833. the parental cells accumulated 2.2-fold more daunonubicin than the resistant subline. However. as the parental cells also expressed Pgp to some extent. they responded to PSC 833 by a 2.4-fold increase in daunorubicin accumulation. In comparison. Interestingly. the growth of sensitive and resistant human hepatoma cell lines remained unaffected by PSC 833 in the same dose range that was applied to the KGla cells. At higher concentrations (> 2.5 Am). the cell counts of both populations were reduced, but the mean values never reached 50% growth inhibition and there was no difference between these two cell types ( Figure  6 ). Thus. a differential effect of PSC 833 could not be demonstrated in the human hepatoma cell lines. As (Tsuruo et al, 1981) . In recent years. several novel agents that are highly potent and specific inhibitors of Pgp have been developed (Ford. 1995) . One of them is PSC 833. which is currently undergoing several clinical trials (Fisher and Sikic. 1995 (Twentyman and Bleehen. 1991) . Verapamil, which also inhibits Pgp. has no effect on the growth of the resistant leukaemia cells in relevant concentrations.
which could be explained by the lower potency of this drug.
m.c.f.
Correspondingly. Hamada and Tsuruo (1986) (Drach et al. 1996 : Raghu et al. 1996 . Moreover. withdrawal of IL-3 has been shown to cause cell death by apoptosis in a murine haematopoietic cell line (Ormerod et al. 1992 (Thompson. 1995) . During apoptosis. endogenous proteases are activated. followed by cytoskeletal disruption. cell shrinkage and activation of nucleases that degrade the chromosomal DNA into oligyonucleosomal fragments (Steller. 1995) .
The presence of degraded DNA within the apoptotic cells was demonstrated by the TIJNEL technique and the hypodiploidy assay. Because cleavage of DNA appears late in the apoptotic process and may be partial or absent. our measurements may have underestimated the degree of apoptosis conferred by PSC 833.
However. the measurements were done after 72 and 96 h exposure to the drua. and the extended exposure allowed detection of accumulated effects. The abundance of hypodiploid pulses from resistant leukaemia cells that emerged after treatment with PSC 833 demonstrated the fragmentation of DNA in these cells. which is typical for late stages of apoptosis (Telford et al. 1994) .
The physiological activation of apoptosis may be conferred by tumour necrosis factor. certain neurotransmitters. calcium or glucocorticoids (Thompson. 1995) . Pharmacological induction of apoptosis has hitherto been shown for cvtotoxic drugs such as doxorubicin. etoposide. taxol and vincristine ( Mivashita and Reed. 1993: Milas et al. 1994) . but activation of apoptosis by a drug sensitizer such as PSC 833 has not been shown previously-. Interestingly. PSC 833 is a highly potent inhibitor of Pgp-mediated C) Cancer Research Campaign 1998
Cytotoxicity of the cyclosponn PSC 833 599 eftlux of druas that are known to induce apoptosis. Thus. PSC 833 may induce apoptosis not only by itself. but also by increasing the intracellular concentration of c'vtotoxics that are both substrates of Pgp and inducers of apoptosis. The apoptotic pathway of PSC 833-induced cvtotoxicitv remains to be identified. but overexpression of Pgp has been associated with increased susceptibility to TNFinduced apoptosis (Malorni et al. 1996) . Therefore. further studies should address the characteristics of the apoptotic process induced bv PSC 833.
The MIDR-modif-ing potential of PSC 833 is currently being studied in several clinical trials (Fisher and Sikic. 1995) . One major advantage of PSC 833 is the low-potential of side-effects. reversible ataxia beina dose-limiting toxicity (Fisher and Sikic. 1995) . In a recent phase I trial. combined treatment with PSC 833 and etoposide did not provide any evidence of immunosuppression or nephrotoxicitv. and the maximum tolerated plasma concentration was 2.5-3 gm (Boote et al. 1996) . The modest and non-selective groWth impairment that was seen in the hepatoma cell lines appeared only at concentrations above the maximum tolerated plasma concentration. In comparison. the half-maximum c'Vtotoxic dose of PSC 833 was 0.2 gmI and 0.7 1.m in the Pp-positive KG 1 a/200 and K562/150 leukaemia cells respectively. However. our in vitro studies were performed in cell culture media supplemented with 10% fetal calf serum. In 100% serum. which is closer to the clinical situation. the activity of PSC 833 is fivefold reduced because of protein binding (Boote et al. 1996) . Thus. one might expect to achieve cytostatic effects in susceptible neoplastic cells at tolerable plasma concentrations of PSC 833.
The present paper reveals hitherto unknown cvtotoxicitv of PSC 833 in vitro. The cytotoxic effect is associated with pa and confined to certain human MDR leukaemia cell types. Further studies are needed to determine whether this effect is coupled with the leukaemia or MDR phenotype or with both. or whether the effect requires activation of a specific apoptotic pathway. In either case. the discriminating cvtotoxicitv of PSC 833 represents a possible therapeutic indication. which warrants consideration during the current clinical evaluation of this drug.
